05.28.2024

Affini-T Therapeutics Announces First Patient Dosed in KRAS G12V Phase 1 Program and Presentation of Trial-in-Progress Poster at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

Press Releases

05.01.2024

Affini-T Therapeutics to Present Data from Its Preclinical Programs Targeting KRAS G12D and TP53 R175H at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting

Press Releases

04.07.2024

Affini-T Therapeutics Presents Preclinical Data from its Oncogenic Driver Programs Targeting KRAS G12D and p53 R175H at the American Association for Cancer Research (AACR) Annual Meeting 2024

Press Releases

ENDPOINTS

06.02.2023

Exclusive: Affini-T taps Sanofi alum to lead hunt for partnerships; Alkermes locks in CEO for oncology spinout

News

ENDPOINTS

04.19.2023

KRAS, one of cancer’s toughest targets, sees a surge of new therapies trying to limit side effects: #AACR23

News

ENDPOINTS

11.28.2022

Endpoints’ 10 biggest stories of 2022

News

05.08.2024

Loss of Heterozygosity is Low for Specific HLA Alleles in Cancer Patients with Driver Mutations

Presentations

05.08.2024

THRIVE™ Non-Viral Targeted Transgene Knock-In Platform Generates Specific and Potent TCR T Cell Products for the Treatment of Solid Cancers

Presentations

04.07.2024

American Association for Cancer Research (AACR) Annual Meeting 2024, Poster #10

Presentations